HUP0203203A2 - Heterociklusos szubsztituált pirazolonok és ilyen vegyületeket tartalmazó gyógyászati készítmények - Google Patents
Heterociklusos szubsztituált pirazolonok és ilyen vegyületeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0203203A2 HUP0203203A2 HU0203203A HUP0203203A HUP0203203A2 HU P0203203 A2 HUP0203203 A2 HU P0203203A2 HU 0203203 A HU0203203 A HU 0203203A HU P0203203 A HUP0203203 A HU P0203203A HU P0203203 A2 HUP0203203 A2 HU P0203203A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkenyl
- alkynyl
- group
- alkyl
- pharmaceutical compositions
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 5
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 title abstract 2
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Chemical class 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- -1 phenyl- Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
Abstract
A találmány általánosságban véve (I) általános képletű heterociklusosszubsztituált pirazolonokra és ezek sztereoizomereire vagygyógyászatilag elfogadható sóira vonatkozik, valamint ilyenvegyületeket tartalmazó gyógyászati készítményekre. Az (I) általánosképletben a helyettesítők jellemző jelentése: Het jelentéseheterociklusos csoport, R1 jelentése hidrogénatom, adott esetbenszubsztituált alkil-, alkenil-, vagy alkinilcsoport, mono- vagydialkilamino, acil- vagy heterociklusos csoport, R2 és R3 jelentésehidrogénatom, adott esetben szubsztituált alkil-, alkenil- vagyalkinilcsoport, vagy heterociklusos csoport; R4 jelentése F, Cl, Br,I, OH, NO2, CN, CF3, alkil-, alkenil-, alkinil-, alkoxi-, cikloalkil-,CO2H, acil-, NH2, mono- vagy dialkil-amino-, fenil-, heteroaril- vagyketocsoport (C=O) és n értéke 0, 1 vagy 2. R5 nincs jelen vagyjelentése H, alkil-, alkenil-, alkinil-, (CH2)r-(cikloalkil)-vagy(CH2)rfenil-csoport, ahol r értéke 0-4. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16337799P | 1999-11-04 | 1999-11-04 | |
US09/702,191 US6455525B1 (en) | 1999-11-04 | 2000-10-31 | Heterocyclic substituted pyrazolones |
PCT/US2000/030226 WO2001032653A1 (en) | 1999-11-04 | 2000-11-01 | Heterocyclic substituted pyrazolones |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0203203A2 true HUP0203203A2 (hu) | 2003-02-28 |
Family
ID=26859595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203203A HUP0203203A2 (hu) | 1999-11-04 | 2000-11-01 | Heterociklusos szubsztituált pirazolonok és ilyen vegyületeket tartalmazó gyógyászati készítmények |
Country Status (21)
Country | Link |
---|---|
US (2) | US6455525B1 (hu) |
EP (1) | EP1226141A1 (hu) |
JP (1) | JP2003513091A (hu) |
KR (1) | KR20020063179A (hu) |
CN (1) | CN1387528A (hu) |
AU (1) | AU1581101A (hu) |
BG (1) | BG106771A (hu) |
BR (1) | BR0015568A (hu) |
CA (1) | CA2389807A1 (hu) |
CZ (1) | CZ20021569A3 (hu) |
EA (1) | EA200200530A1 (hu) |
HK (1) | HK1048632A1 (hu) |
HU (1) | HUP0203203A2 (hu) |
IL (1) | IL149420A0 (hu) |
IS (1) | IS6366A (hu) |
MX (1) | MXPA02004415A (hu) |
NO (1) | NO20022095L (hu) |
PL (1) | PL355296A1 (hu) |
SK (1) | SK6172002A3 (hu) |
TR (1) | TR200201225T2 (hu) |
WO (1) | WO2001032653A1 (hu) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US7060822B1 (en) * | 1999-07-30 | 2006-06-13 | Abbott Gmbh & Co. Kg | 2-pyrazolin-5-ones |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
WO2003011287A1 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
CN100409840C (zh) * | 2002-01-10 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | GSK-3β抑制剂在制备增加骨生成的药物中的应用 |
SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
WO2004031203A1 (ja) * | 2002-10-04 | 2004-04-15 | Kissei Pharmaceutical Co., Ltd. | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2004092395A2 (en) * | 2003-04-08 | 2004-10-28 | Baylor College Of Medicine | Modulators of telomere stability |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
WO2005061463A1 (en) | 2003-12-23 | 2005-07-07 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
WO2005069906A2 (en) * | 2004-01-16 | 2005-08-04 | Yale University | Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases |
UA86962C2 (en) * | 2004-02-20 | 2009-06-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Viral polymerase inhibitors |
US7253168B2 (en) * | 2004-04-07 | 2007-08-07 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
WO2005110989A1 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
US7550598B2 (en) * | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2006034121A1 (en) * | 2004-09-17 | 2006-03-30 | Henry Ford Health System | Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CN101119988B (zh) * | 2005-02-16 | 2013-03-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
WO2006087530A1 (en) * | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
KR20080015409A (ko) * | 2005-05-16 | 2008-02-19 | 아스트라제네카 아베 | 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체 |
JPWO2006129583A1 (ja) * | 2005-05-30 | 2009-01-08 | 株式会社ジーンケア研究所 | ピラゾロン誘導体 |
EP1900728A1 (en) * | 2005-05-30 | 2008-03-19 | Genecare Research Institute Co., Ltd | Pharmaceutical composition comprising pyrazolone derivative |
EP1919875A2 (en) * | 2005-06-21 | 2008-05-14 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
WO2007019674A1 (en) * | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP2009513615A (ja) * | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体 |
MX2008013400A (es) | 2006-04-19 | 2008-11-10 | Astellas Pharma Inc | Derivado de azolcarboxamida. |
MX2009003793A (es) | 2006-10-09 | 2009-12-14 | Takeda Pharmaceutical | Inhibidores de cinasa. |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
WO2008129255A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
CN101687863B (zh) * | 2007-05-04 | 2012-09-12 | 阿斯利康(瑞典)有限公司 | 氨基-噻唑基-嘧啶衍生物及其治疗癌症的用途 |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
CA2693694A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Massachusetts | Mixed lineage kinases and metabolic disorders |
AU2008314922B2 (en) | 2007-10-24 | 2013-08-29 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
CN101801195A (zh) * | 2007-11-21 | 2010-08-11 | 帝国制药美国公司 | 吡唑啉酮衍生物乳液制剂 |
WO2009088054A1 (ja) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | 精巣の疼痛又は不快感行動及び頻尿併発モデル動物 |
US20110092452A1 (en) * | 2008-03-05 | 2011-04-21 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
US8365773B2 (en) * | 2008-03-14 | 2013-02-05 | Mcp Industries, Inc. | Valve device and testing method |
US20090286832A1 (en) * | 2008-05-15 | 2009-11-19 | Kiichiro Nabeta | Narcotic emulsion formulations for treatment of surgical pain |
EP2288602A1 (en) * | 2008-06-11 | 2011-03-02 | AstraZeneca AB | Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
US20100034752A1 (en) * | 2008-08-11 | 2010-02-11 | Toru Hibi | Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same |
BRPI0919488A2 (pt) * | 2008-09-30 | 2015-12-01 | Astrazeneca Ab | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
WO2010059727A1 (en) * | 2008-11-20 | 2010-05-27 | Teikoku Pharma Usa, Inc. | Pyrazalone derivative formulations |
EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
AU2010218424B2 (en) | 2009-02-26 | 2014-02-13 | Techno Guard Co., Ltd. | Narcotic emulsion formulations for treatment of cancer pain |
EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
EP2785184B1 (en) | 2011-11-30 | 2020-06-10 | Emory University | Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2935228B9 (en) | 2012-12-20 | 2017-12-06 | Inception 2, Inc. | Triazolone compounds and uses thereof |
EP3105205A4 (en) | 2014-02-14 | 2017-08-02 | Inception 2, Inc. | Pyrazolone compounds and uses thereof |
CN104860932B (zh) * | 2015-05-13 | 2018-01-12 | 安阳师范学院 | 一种吡唑啉酮类化合物及其应用 |
CN107935905B (zh) * | 2017-11-28 | 2021-09-17 | 大理大学 | Indiacens A的合成方法 |
CN114829357A (zh) * | 2019-10-28 | 2022-07-29 | 中国科学院上海药物研究所 | 五元杂环氧代羧酸类化合物及其医药用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2081595A1 (en) | 1970-03-31 | 1971-12-10 | Serdex | 1,3-diphenyl-2-pyrazolin-5-ones - as analgesic and antiinflammatory agents |
FR2224141A2 (en) | 1973-04-05 | 1974-10-31 | Serdex Etudes Rech Diffus Expl | 1,3-diphenyl-4-hydroxymethylene-pyrazolinones - their salts and formyl derivs, with analgesic and antiinflammatory activity |
DE2045049A1 (de) | 1970-09-11 | 1972-03-23 | Dr Karl Thomae GmbH, 7950 Biberach | Neue Nitrofurandenvate und Ver fahren zu ihrer Herstellung |
IT1032161B (it) * | 1974-12-09 | 1979-05-30 | Minnesota Mining & Mfg | Coloranti merocianinici quaterna rizzati e loro uso per sensibiliz zare spettralmente emulsioni positive dirette agli alogenuri d argento |
DE3728278A1 (de) | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
DE3941240A1 (de) | 1989-12-14 | 1991-06-20 | Bayer Ag | Pyrazolin-5-on-derivate |
AU690527B2 (en) * | 1992-12-17 | 1998-04-30 | Pfizer Inc. | Pyrazoles having CRF antagonist activity |
US5780437A (en) * | 1995-12-14 | 1998-07-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JPH10151868A (ja) | 1996-11-21 | 1998-06-09 | Konica Corp | 黒色画像形成用色素混合物及びそれを用いた感熱転写記録材料ならびに感熱転写記録方法 |
US6034099A (en) | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
DE19909237A1 (de) | 1999-03-03 | 2000-09-07 | Merck Patent Gmbh | Pyrazol-3-on-derivate |
CN1193026C (zh) | 1999-07-30 | 2005-03-16 | 艾博特股份有限两合公司 | 2-吡唑啉-5-酮 |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
-
2000
- 2000-10-31 US US09/702,191 patent/US6455525B1/en not_active Expired - Lifetime
- 2000-11-01 KR KR1020027005807A patent/KR20020063179A/ko not_active Application Discontinuation
- 2000-11-01 HU HU0203203A patent/HUP0203203A2/hu unknown
- 2000-11-01 AU AU15811/01A patent/AU1581101A/en not_active Abandoned
- 2000-11-01 IL IL14942000A patent/IL149420A0/xx unknown
- 2000-11-01 BR BR0015568-3A patent/BR0015568A/pt not_active Application Discontinuation
- 2000-11-01 WO PCT/US2000/030226 patent/WO2001032653A1/en not_active Application Discontinuation
- 2000-11-01 PL PL00355296A patent/PL355296A1/xx unknown
- 2000-11-01 SK SK617-2002A patent/SK6172002A3/sk unknown
- 2000-11-01 MX MXPA02004415A patent/MXPA02004415A/es unknown
- 2000-11-01 JP JP2001534804A patent/JP2003513091A/ja active Pending
- 2000-11-01 CN CN00814898A patent/CN1387528A/zh active Pending
- 2000-11-01 EP EP00978338A patent/EP1226141A1/en not_active Withdrawn
- 2000-11-01 CA CA002389807A patent/CA2389807A1/en not_active Abandoned
- 2000-11-01 CZ CZ20021569A patent/CZ20021569A3/cs unknown
- 2000-11-01 TR TR2002/01225T patent/TR200201225T2/xx unknown
- 2000-11-01 EA EA200200530A patent/EA200200530A1/ru unknown
-
2002
- 2002-04-29 IS IS6366A patent/IS6366A/is unknown
- 2002-05-02 NO NO20022095A patent/NO20022095L/no not_active Application Discontinuation
- 2002-06-04 BG BG106771A patent/BG106771A/xx unknown
- 2002-08-22 US US10/225,670 patent/US6831075B2/en not_active Expired - Lifetime
-
2003
- 2003-01-27 HK HK03100691.9A patent/HK1048632A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BG106771A (en) | 2003-03-31 |
US20030162775A1 (en) | 2003-08-28 |
NO20022095L (no) | 2002-06-11 |
EA200200530A1 (ru) | 2002-10-31 |
WO2001032653A1 (en) | 2001-05-10 |
BR0015568A (pt) | 2003-06-10 |
US6831075B2 (en) | 2004-12-14 |
JP2003513091A (ja) | 2003-04-08 |
EP1226141A1 (en) | 2002-07-31 |
MXPA02004415A (es) | 2004-09-10 |
SK6172002A3 (en) | 2003-01-09 |
IL149420A0 (en) | 2002-11-10 |
IS6366A (is) | 2002-04-29 |
TR200201225T2 (tr) | 2002-08-21 |
AU1581101A (en) | 2001-05-14 |
CA2389807A1 (en) | 2001-05-10 |
NO20022095D0 (no) | 2002-05-02 |
PL355296A1 (en) | 2004-04-05 |
HK1048632A1 (zh) | 2003-04-11 |
CZ20021569A3 (cs) | 2003-03-12 |
US6455525B1 (en) | 2002-09-24 |
KR20020063179A (ko) | 2002-08-01 |
CN1387528A (zh) | 2002-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203203A2 (hu) | Heterociklusos szubsztituált pirazolonok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
DK0590919T3 (da) | Terapeutiske midler mod Parkinsons sygdom | |
HUP0300350A2 (hu) | Új 3-amino-azetidin-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0400887A2 (hu) | Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók | |
CA2140598A1 (en) | Prolineamide derivatives | |
DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
HUP0103511A2 (hu) | Oxazolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
ATE241617T1 (de) | Pyrimidinverbindungen | |
PL328310A1 (en) | Derivatives of quinazoline | |
HUP0400710A2 (hu) | Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303458A2 (hu) | 6-Helyettesített pirido-pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203367A2 (hu) | Benzilidén-tiazolidin-dionok és analógjaik, valamint ezek alkalmazása cukorbetegség kezelésében | |
HUP9701596A2 (hu) | 2,4-Diamino-1,3,5-triazin-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0401083A2 (hu) | 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
ATE291018T1 (de) | Pyrazol verbindungen und ihre verwendung | |
BR0015195A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas | |
RS111104A (en) | 1-/(indol-3-yl)carbonyl/piperazine derivatives | |
HUP0301706A2 (hu) | Comt gátló hatással rendelkezż kumarinszármazékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
CA2251820A1 (en) | Substituted benzylamines and their use for the treatment of depression | |
HUP0300402A2 (hu) | [Kinolil-(4-piperidinilidén)-metil]-benzamid-származékok fájdalom kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
CO5540322A2 (es) | Nuevos derivados heterociclicos que comprenden un anillo de tetrahidroisoquinolina y uso farmaceutico de los mismos | |
HUP0101469A2 (hu) | 5-[(2-Imidazolidinilidén)-amino]-benzimidazol-származékok, előállításuk és alkalmazásuk javított metabolikus stabilitású alfa-adrenoceptor agonistákként | |
HUP9800817A2 (hu) | Halogén-alk(en)oxi-szubsztituenseket tartalmazó szulfonil-amino-karbonil-triazolinon-származékok, intermedierjeik, előállításuk és alkalmazásuk, hatóanyagként ezeket a vegyületeket tartalmazó herbicid vagy fungicid készítmények | |
HUP0500203A2 (hu) | Acil-3-karboxi-fenil-karbamid-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0102011A2 (hu) | Makrolid LHRH anatgonista vegyületek és alkalmazásuk, eljárás előállításukra valamint e vegyületeket tartalmazó gyógyászati készítmények |